Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641469 | 0.95 | PPARG (0.46) | SOAT2SOAT1PPARGEPHX2FAAH | |
| SCHEMBL2641465 | 0.95 | PPARG (0.46) | SOAT2SOAT1PPARGEPHX2FAAH | |
| SCHEMBL14935142 | 0.95 | PPARG (0.46) | SOAT2SOAT1PPARGEPHX2FAAH | |
| SCHEMBL2641466 | 0.95 | PPARG (0.46) | SOAT2SOAT1PPARGEPHX2FAAH | |
| SCHEMBL14935141 | 0.95 | PPARG (0.46) | SOAT2SOAT1PPARGEPHX2FAAH | |
| SCHEMBL15027984 | 0.94 | ALOX5 (0.39) | SOAT2SOAT1PPARGEPHX2FAAH | |
| SCHEMBL16705768 | 0.90 | PRKCE (0.42) | SOAT2SOAT1EPHX2FAAHCES1 | |
| SCHEMBL15027682 | 0.89 | PPARG (0.42) | PPARGFAAHPPARA | |
| SCHEMBL16520369 | 0.89 | PPARG (0.46) | SOAT2SOAT1PPARGEPHX2FAAH | |
| SCHEMBL16705753 | 0.88 | SOAT2 (0.38) | SOAT2SOAT1PPARGEPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170135962-A1 | NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9402816-B2 | Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery | SIMA THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150133519-A1 | NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133519-A1 | NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | CYP46A1, CETP, LIPC | SOAT2 209/4885SOAT1 123/4885PPARG 1750/4885 |
| US-20170135962-A1 | NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | CYP46A1, CETP, LIPC | SOAT2 209/4885SOAT1 123/4885PPARG 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.